scanX
Glenmark Pharmaceuticals

Glenmark Pharmaceuticals

1,843.30
+28.20
(1.55%)
hide
Key Fundamentals
Add Ratio
Market Cap
51,222.30 Cr
EPS
37.11
PE Ratio
67.98
Dividend Yield
0.14 %
Industry
Healthcare
52 Week High
2,284.80
52 Week Low
1,275.50
PB Ratio
5.79
Debt to Equity
0.22
Sector
Pharmaceuticals
Analyst Rating and Forecast
- By Refinitiv from9 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+77.78 %
+77.78 %
Hold
Hold+11.11 %
+11.11 %
Sell
Sell+11.11 %
+11.11 %
Forecast For
Actual

Company News

View All News
Caret
positive
Glenmark Pharmaceuticals to Launch Ropivacaine Injection in November 20256 days ago
Glenmark Pharmaceuticals plans to introduce Ropivacaine Hydrochloride Injection USP in November 2025. The product will compete with Naropin®, which generates approximately $20.9 million in annual revenue.
neutral
Glenmark Pharma Sets October 1 as Last Day to Buy Shares for Interim Dividend EligibilityOct 01, 2025
Glenmark Pharmaceuticals has set October 1 as the final day for investors to purchase shares to qualify for its interim dividend, with the record date falling on October 3. The board approved an interim dividend of Rs 2.5 per equity share on face value of Rs 1 per share for financial year 2026, totaling Rs 70.5 crore. The dividend payment will be made within 30 days of declaration. Due to India's T+1 settlement cycle and October 2 being a market holiday, shares must be purchased by October 1 to qualify for the payout.
negative
Glenmark Pharmaceuticals Announces Rs 2.5 Interim Dividend, Reports 86% Profit DropSep 28, 2025
Glenmark Pharmaceuticals will trade ex-dividend this week, issuing an interim dividend of Rs 2.5 on October 3. Due to India's T+1 settlement cycle, investors must purchase shares by October 1 to qualify for the dividend, as October 2 is a market holiday for Gandhi Jayanti. The company's consolidated net profit fell 86% in the first quarter, dropping to Rs 46.80 crore from Rs 340.2 crore in the same quarter of the previous fiscal year, despite a one-time gain of Rs 323 crore in the June quarter.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,715.90
#1 4,04,767.80
38.94
#1 54,729.00
9.71
#1 10,980
-19.84
67.74
Divis Laboratories
6,512.00
1,70,921.90
74.05
9,712.00
18.67
2,191
26.74
60.77
Cipla
1,581.10
1,26,663.90
23.55
28,409.50
7.12
5,291
9.88
52.88
Torrent Pharmaceuticals
3,599.30
1,21,045.00
60.48
11,539.40
6.99
1,911
19.91
54.44
Dr Reddys Laboratories
1,250.90
1,07,615.10
#1 18.77
33,741.20
16.73
5,725
-0.38
45.01
Zydus Life Science
1,002.90
1,00,749.20
21.39
23,511.00
18.55
4,615
2.60
51.23
Mankind Pharma
2,443.70
99,330.30
51.89
12,744.20
#1 20.90
2,007
-18.14
44.93
Lupin
1,955.90
87,637.50
23.57
22,909.50
13.74
3,306
#1 51.64
51.72
Alkem Laboratories
5,535.00
64,947.70
27.84
13,458.30
3.70
2,216
21.39
55.26
Aurobindo Pharma
1,111.70
63,853.30
19.01
32,345.60
9.43
3,484
-10.24
55.31

Automatic Screeners on ScanX

Community
Day 1 Unusual Volume
Community
Resistance 1 Breached
Growth Rate
Revenue Growth
6.18 %
Net Income Growth
-157.19 %
Cash Flow Change
-211.78 %
ROE
-150.71 %
ROCE
146.21 %
EBITDA Margin (Avg.)
14.05 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
1,754
1,631
1,880
1,749
2,211
1,986
2,171
2,478
2,373
2,345
2,253
2,148
2,317
2,268
2,847
2,401
2,565
2,285
2,845
2,672
2,788
2,396
2,879
2,787
2,838
3,005
3,112
3,155
3,068
2,903
3,069
3,272
3,062
3,018
3,281
2,625
3,814
3,255
3,440
3,333
3,232
3,086
Expenses
1,682
1,288
1,506
1,408
2,003
1,590
1,775
1,770
2,094
1,786
1,868
1,881
1,953
1,819
2,141
2,120
2,199
1,981
2,365
2,296
2,302
1,867
2,400
2,257
2,337
2,391
2,557
2,659
2,638
2,346
2,539
2,626
3,402
2,651
3,071
2,792
3,005
2,656
2,832
2,787
3,068
3,007
EBITDA
73
343
374
341
208
395
396
708
279
559
385
267
365
449
706
280
366
304
480
376
487
529
480
531
502
614
555
497
430
558
530
646
-340
367
211
-168
808
599
608
546
164
79
Operating Profit %
4 %
21 %
20 %
19 %
9 %
17 %
18 %
28 %
14 %
23 %
16 %
13 %
13 %
15 %
16 %
16 %
13 %
13 %
14 %
13 %
15 %
19 %
17 %
18 %
17 %
19 %
18 %
15 %
11 %
14 %
15 %
14 %
-15 %
12 %
3 %
-13 %
0 %
18 %
17 %
16 %
5 %
2 %
Depreciation
65
65
59
52
58
64
69
63
69
78
75
75
74
79
82
83
81
91
94
106
126
113
104
115
111
113
123
119
132
147
146
152
135
142
141
147
151
118
120
123
125
130
Interest
40
42
43
47
48
43
63
62
70
71
70
71
74
79
85
89
82
93
90
96
99
94
81
95
83
76
69
67
87
60
83
97
109
112
122
134
149
40
49
52
67
58
Profit Before Tax
-10
257
303
274
209
348
315
655
173
444
273
154
249
327
580
154
240
160
347
271
318
358
339
348
338
444
385
343
270
408
337
435
-542
151
-6
-403
555
462
473
456
8
96
Tax
-20
75
87
78
60
121
92
178
-11
111
59
49
97
94
166
38
79
51
92
80
98
104
105
100
104
137
110
103
97
197
58
144
-139
-22
56
-72
1,770
122
118
108
4
49
Net Profit
11
183
216
196
149
227
224
477
184
333
214
105
152
233
414
116
162
109
256
191
220
254
234
248
234
307
275
240
173
211
279
291
-403
173
-62
-331
-1,214
340
355
348
4
47
EPS in ₹
0.39
6.66
7.66
6.95
5.28
8.04
7.92
16.91
6.51
11.81
7.59
3.71
5.37
8.26
14.67
4.12
5.73
3.87
9.06
6.76
7.81
9.00
8.29
8.80
8.29
10.86
9.13
7.86
5.51
6.82
9.23
9.66
-15.18
5.31
-2.90
-12.45
-43.17
12.06
12.55
12.33
0.16
1.66
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
9,688
10,193
11,764
12,595
13,296
14,685
15,604
17,083
19,372
14,359
16,050
Fixed Assets
2,836
2,594
2,755
3,030
3,670
5,029
5,129
5,887
6,202
4,210
4,487
Current Assets
5,323
5,904
6,875
6,989
6,697
6,804
7,360
8,282
9,874
7,428
9,296
Capital Work in Progress
492
543
708
1,122
1,399
1,222
1,382
1,010
1,251
662
835
Investments
0
17
16
15
30
25
25
50
45
790
56
Other Assets
6,359
7,039
8,285
8,429
8,197
8,410
9,068
10,137
11,873
8,697
10,672
Total Liabilities
9,688
10,193
11,764
12,595
13,296
14,685
15,604
17,083
19,372
14,359
16,050
Current Liabilities
3,711
3,999
2,703
3,288
4,021
4,126
4,201
4,689
5,046
5,819
5,967
Non Current Liabilities
2,976
2,564
4,569
4,144
3,670
4,489
4,338
2,956
4,487
693
1,234
Total Equity
3,000
3,629
4,492
5,163
5,605
6,070
7,064
9,438
9,839
7,848
8,849
Reserve & Surplus
2,973
3,601
4,464
5,135
5,577
6,042
7,036
9,058
9,446
7,820
8,821
Share Capital
27
28
28
28
28
28
28
28
28
28
28
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-31
93
199
177
-297
174
28
272
33
215
17
Investing Activities
-712
-950
-1,001
-1,003
-883
-774
-662
-316
-515
4,387
58
Operating Activities
482
345
657
1,648
1,324
1,392
1,131
1,109
625
-265
-828
Financing Activities
199
699
543
-469
-739
-445
-442
-521
-78
-3,906
787
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
46.63 %
46.63 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.64 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
24.80 %
23.71 %
21.38 %
20.98 %
23.05 %
23.51 %
23.16 %
20.62 %
20.73 %
DIIs
3.82 %
4.94 %
5.09 %
7.08 %
6.62 %
6.01 %
10.64 %
10.69 %
10.41 %
9.11 %
10.32 %
10.92 %
13.36 %
13.92 %
13.21 %
13.85 %
14.60 %
17.64 %
18.61 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
Public / Retail
15.92 %
14.43 %
16.02 %
15.88 %
15.88 %
16.32 %
16.47 %
16.72 %
16.90 %
15.20 %
14.83 %
14.77 %
14.83 %
14.58 %
13.61 %
12.65 %
12.32 %
11.69 %
10.81 %
Others
33.63 %
34.00 %
32.25 %
30.40 %
30.86 %
31.02 %
26.21 %
25.91 %
26.01 %
29.01 %
3.37 %
3.92 %
3.75 %
3.83 %
3.45 %
3.31 %
3.24 %
3.37 %
3.16 %
No of Share Holders
2,50,849
2,75,801
3,29,870
3,17,383
3,10,516
3,12,473
3,13,540
3,00,106
2,85,461
2,36,908
2,32,685
2,09,931
1,99,451
1,92,630
1,93,949
1,95,059
1,92,724
1,90,210
1,98,789

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 2 2 2 2 2.5 2.5 2.5 2.5 2.5 2.5
Dividend Yield (%) 0.23 0.38 0.31 0.97 0.54 0.57 0.56 0.26 0.16 0.14

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
10 Sept 2021 DIVIDEND Dividend
₹ 2.50 /share
 08 Sept 2021 606.70 524.55
14 Sept 2022 DIVIDEND Dividend
₹ 2.50 /share
 12 Sept 2022 397.90 393.35
19 Sept 2023 DIVIDEND Dividend
₹ 2.50 /share
 18 Sept 2023 604.10 850.75
29 Sept 2023 ANNUAL GENERAL MEETING Annual General Meeting
NA
 29 Sept 2023 749.15 776.95
17 Sept 2024 DIVIDEND Dividend
₹ 2.50 /share
 13 Sept 2024 1,027.60 1,741.85
27 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 27 Sept 2024 1,684.85 1,676.95
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 14 Nov 2024 1,673.95 1,539.40
14 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 14 Feb 2025 1,436.30 1,411.20
23 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 23 May 2025 1,398.20 1,431.10
14 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 14 Aug 2025 2,067.80 2,029.30
15 Sept 2025 DIVIDEND Dividend
₹ 2.50 /share
 15 Sept 2025 1,431.10 2,132.50
26 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 26 Sept 2025 1,941.60 2,031.05
03 Oct 2025 DIVIDEND Dividend
₹ 2.50 /share
 03 Oct 2025 2,031.05 1,958.65

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release6 days ago
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 26, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 26, 2025
Corporate Action-Board approves DividendSep 26, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On 26Th September 2025Sep 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 24, 2025
Revision In Intimation Of Record Date For Interim DividendSep 22, 2025
Closure of Trading WindowSep 22, 2025
Intimation Of Record Date For Interim DividendSep 22, 2025
Board Meeting Intimation for Considering And Approving Payment Of Interim DividendSep 22, 2025
Announcement under Regulation 30 (LODR)-Credit RatingSep 19, 2025
Transfer Of The Companys Consumer Care BusinessSep 15, 2025
Intimation Regarding Upfront Payment ReceivedSep 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 01, 2025
Intimation Of Record Date For DividendAug 29, 2025
Business Responsibility and Sustainability Reporting (BRSR)Aug 29, 2025
Reg. 34 (1) Annual Report.Aug 29, 2025
Notice Of 47Th Annual General Meeting Of The Company For F.Y. 2024-25 As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 28, 2025
Intimation Of Book Closure Pursuant To Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 22, 2025
Update On Acquisition Of Securities Of O2 Renewable Energy XXIV Private LimitedAug 20, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 14, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 14, 2025
Transfer Of The Companys Consumer Care Business To Its Newly Incorporated Wholly Owned Subsidiary Glenmark Consumer Care LimitedAug 14, 2025
Appointment Of Secretarial AuditorAug 14, 2025
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sAug 14, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateAug 14, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14Th August 2025Aug 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 14, 2025
Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended 30Th June 2025Aug 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 08, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Aug 06, 2025
Closure of Trading WindowAug 04, 2025
Board Meeting Intimation for Considering And Approving The Financial Results For The First Quarter Ended June 30 2025Aug 04, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotAug 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 25, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJul 23, 2025
Audio Recording Of The Glenmark Pharmaceuticals Limited - Investor Day 2025Jul 23, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 16, 2025
Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015Jul 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 02, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Axis Midcap Direct Plan-Growth
0.28%
412540
0.26%
0.28%
Bandhan Large & Mid Cap Fund Direct-Growth
1.12%
410157
0.72%
0.35%
Edelweiss Balanced Advantage Fund Direct-Growth
0.65%
267999
0.41%
0.38%
Mahindra Manulife Mid Cap Fund Direct - Growth
3.11%
205310
0.99%
0.99%
Tata Mid Cap Direct Plan-Growth
2.32%
200000
0.76%
0.61%
Nippon India Arbitrage Fund Direct-Growth
0.80%
-199500
-0.24%
-0.42%
Invesco India Arbitrage Fund Direct-Growth
0.41%
-188250
-0.17%
-0.03%
Axis Large & Mid Cap Fund Direct-Growth
0.24%
180511
0.24%
0.24%
HDFC Arbitrage Fund Wholesale Direct-Growth
0.07%
-174000
-0.15%
-0.20%
Kotak Arbitrage Fund Direct-Growth
0.36%
162750
0.06%
-0.03%
Bajaj Finserv Large and Mid Cap Fund Direct-Growth
2.29%
162656
1.49%
1.41%
Aditya Birla Sun Life Mid Cap Direct Fund-Growth
0.76%
-110229
-0.35%
-1.10%
Axis India Manufacturing Fund Direct-Growth
0.85%
101487
0.37%
0.33%
Edelweiss Arbitrage Fund Direct-Growth
0.81%
78750
0.10%
0.10%
Edelweiss Aggressive Hybrid Fund Direct - Growth
0.48%
78064
0.48%
0.48%
ICICI Prudential Equity Arbitrage Direct-Growth
0.35%
-76125
-0.04%
-0.09%
HDFC Mid Cap Fund Direct-Growth
2.87%
75935
0.00%
-0.20%
Bandhan Multi Cap Fund Direct-Growth
0.50%
70000
0.50%
0.50%
Motilal Oswal Small Cap Fund Direct - Growth
2.21%
61118
0.18%
0.46%
Tata Arbitrage Fund Direct - Growth
0.52%
56250
0.05%
0.08%
Aditya Birla Sun Life Arbitrage Fund Direct-Growth
0.39%
-56250
-0.02%
-0.05%
Mahindra Manulife Multi Cap Fund Direct - Growth
3.38%
54000
0.18%
-0.10%
Edelweiss Business Cycle Fund Direct-Growth
2.67%
49213
0.64%
0.96%
Bandhan Midcap Fund Direct-Growth
0.50%
47576
0.50%
0.50%
SBI Arbitrage Opportunities Fund Direct-Growth
0.37%
-46875
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
25.29
ATR(14)
Volatile
43.13
STOCH(9,6)
Oversold
8.27
STOCH RSI(14)
Oversold
1.86
MACD(12,26)
Bearish
-7.73
ADX(14)
Strong Trend
39.27
UO(9)
Bullish
28.13
ROC(12)
Downtrend And Accelerating
-6.23
WillR(14)
Oversold
-87.88
Bearish
2
Neutral
3
Bullish
4

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd is an Indian research-led global pharmaceutical company founded in 1977. It focuses on developing and manufacturing branded generics, generic drugs, and over-the-counter products in therapeutic areas like respiratory, dermatology, and oncology. The company has a significant presence in emerging markets and operates 14 manufacturing facilities across several countries. Glenmark is involved in drug discovery for new chemical and biological entities, with molecules in various stages of development. It has a strong generics business serving markets like the US and Europe, and an active pharmaceutical ingredients business selling to over 80 countries. The company has made several acquisitions and licensing deals to expand its product portfolio and global reach. Glenmark has launched numerous products across various therapeutic segments and markets, including innovative combinations and first-to-market generics. It has a substantial pipeline of ANDAs filed with the US FDA and continues to receive approvals for new generic products.
Website
https://www.glenmarkpharma.com
Chairperson NameGlenn Saldanha
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Candlestick Screeners
Intraday Screeners
Fundamental Screeners
Technical Screeners
Price & Volume Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104